Orasis Pharmaceuticals used the SECO International 2026 optometry conference to intensify its focus on presbyopia education and its pilocarpine-based eye drop strategy. The company promoted a live “MythBusters” style breakfast symposium, accessible both in person and via livestream, aimed at dispelling misconceptions around pilocarpine.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Throughout the week, Orasis highlighted its SECO Booth 133 as a hub for clinical discussions with eye-care professionals. The firm underscored that education and data-driven dialogue are central to building prescriber confidence in pilocarpine-based presbyopia therapies.
A key scientific element of its presence was a poster session led by Mark Dunbar, O.D., F.A.A.O., examining concentration-dependent effects of low-concentration pilocarpine. This emphasis on dosing, formulation, and safety profile is designed to differentiate Orasis’s approach in a crowded presbyopia eye-drop market.
The company’s materials directed clinicians to detailed safety, risk, and benefit information for its therapy, aligning outreach with regulatory expectations. By actively addressing perceived “pilocarpine myths,” Orasis is working to manage safety perceptions that could otherwise impede adoption.
From a financial perspective, these initiatives signal continued commercial groundwork rather than new clinical or regulatory milestones. Expanded visibility among target prescribers may support future uptake and competitive positioning once broader market access is secured.
Overall, Orasis Pharmaceuticals devoted the week to strengthening its educational and scientific profile in presbyopia and pilocarpine, using SECO 2026 as a platform to engage clinicians and reinforce the clinical case for its treatment candidate.